EXPERT PERSPECTIVE — A meeting – albeit virtual – between President Joe Biden and Chinese President Xi Jinping finally happened.  It was a cordial and reportedly candid exchange that hopefully cooled some of the tension between the U.S. and China.

President Biden captured the essence of the meeting with his concern that this tension “does not veer into conflict, whether intended or unintended.”  President Xi said, “China and the U.S. need to increase communications and cooperation” and “respect each other and coexist in peace.”

It’s hard to believe that in 1979, when formal U.S. – China diplomatic relations were established, Chinese President Deng Xiaoping looked to the U.S. as the country that would provide the investment, technology, and unlimited access to our best universities.  And the U.S. didn’t disappoint.  Investment and sophisticated technology flowed to China, with hundreds of thousands of Chinese students enrolling in our universities.  Strategic bilateral cooperation initially contributed to the defeat of the Soviet Union in Afghanistan, with joint efforts to address international terrorism and nuclear proliferation.

So, during the span of forty-two years, relations have gone from close economic and strategic cooperation to a concern about conflict, intended or unintended.  Understandably, scholars will spend considerable time analyzing what went wrong. 

What is important now is that U.S. – China relations move in a more positive direction.  That tension over China’s aggression against Taiwan, the militarization of islands and reefs in the South China Sea, internment camps for Uyghurs in Xinjiang, the national security law in Hong Kong that suppresses democratic protests and the theft of intellectual property all must be candidly discussed by our diplomats and leaders to avoid misunderstanding and accidental conflict.

President Biden said Washington continues to have a “one China” policy and “opposes unilateral efforts to change the status quo.”  President Xi reportedly said, “Beijing will take decisive measures if the pro-Taiwan independence movement crosses a red line.”

The three communiques and the Taiwan Relations Act of 1979 specifically states that, inter alia, “the United States decision to establish diplomatic relations with the People’s Republic of China rests upon the expectation that the future of Taiwan will be determined by peaceful means; to consider any effort to determine the future of Taiwan by other than peaceful means, including by boycotts or embargoes, is a threat to the peace and security of the Western Pacific area and of grave concern to the United States.”

The challenge for the U.S. and China is to address Taiwan and a myriad of other irritants in the bilateral relationship to ensure that no one issue, or series of issues leads to conflict.  Toning down the rhetoric and pursuing a policy of substantive and sustained communications, especially by our diplomats, would be a necessary first step.


The Cipher Brief hosts private briefings with the world’s most experienced national and global security experts.  Become a member today.


The annual Economic and Strategic Dialogue with China, led by the heads of State Department and Treasury and their counterparts in Beijing was established to oversee progress in addressing these and other challenging issues.  A forum of this type, with announcements to ensure that the public is kept apprised of the issues and the work being done to resolve these issues, is of value, only if this dialogue is substantive and not just ceremonial.

This virtual presidential summit can be transformative if, in addition to addressing these and other irritants, it also addresses the opportunity to cooperate on a multitude of geopolitical issues that affect the security of the U.S. and China – and the world.

I’ll start with the nuclear issue and the fact that there’s minimal dialogue with China on its nuclear program.  And given recent reporting on the three sites in China with the construction of hundreds of missile silos and the recent DIA report that China, by 2030, will have a nuclear arsenal of 1000 nuclear warheads is of concern.  Ideally, China should be part of New Start arms control negotiations with the U.S. and Russia.  But they previously refused to join in this or any other arms control dialogue.  At a minimum, China should be responsive to a dialogue with the U.S. on nuclear-related issues, to include their recent test of two hypersonic missiles.

A separate but equally important dialogue with China is on cyber, to ensure that the cyber domain is not weaponized and used against our private sector for economic advantage.  Also, to ensure that outer space is used exclusively for peaceful purposes.

There are a multitude of global issues requiring bilateral cooperation.  We recently saw some U.S. – China cooperation on climate change at the Glasgow COPS 26 UN Climate Change Conference.  Obviously, more must be done, but this is a positive first step.

Other issues, like North Korea can and should be addressed now.  China has unique leverage with a North Korea that relies on China for its economic survival.  China can use that leverage to get North Korea to return to negotiations and to convince the North that complete and verifiable denuclearization, in return for significant deliverables, is in North Korea’s interest.

With over five million global casualties and over 760,000 deaths in the U.S. due to COVID-19, it should be obvious that greater bilateral cooperation on this and future pandemics is necessary.


Go beyond the headlines with expert perspectives on today’s news with The Cipher Brief’s Daily Open-Source Podcast.  Listen here or wherever you listen to podcasts.


Bilateral cooperation on nuclear proliferation, countering international terrorism, the trafficking of narcotics and confronting international organized crime are just some of the global issues that affect the security of the U.S. and China and the global community.  Failure to cooperate on these and other international issues is not only a security imperative, but a moral responsibility of all great powers.

Finally, with the Taliban back in control in Afghanistan, the U.S. and China have a shared goal: ensuring that the Taliban does not permit Al Qaeda and other terrorist organizations to once again use Afghanistan as a base for its international terrorist operations. China has engaged this Taliban government and should use its significant financial leverage to ensure that all terrorist groups are permanently removed from Afghanistan.

Xi Jinping was just anointed by the Chinese Communist Party as one of its revered leaders, with Mao Zedong and Deng Xiaoping.  The Party congress next year will likely give Xi a third five-year term as the Party’s Secretary General.  There are a multitude of domestic issues requiring Xi’s and the Party’s attention, to include a campaign of “common prosperity” – addressing the disparity of wealth in a China governed by a capitalist system with Chinese characteristics.

Hopefully, President Xi Jinping will work with President Joe Biden to ensure that the two great powers, consumed with domestic issues, will also address the myriad of international issues requiring immediate and long-term attention and avoid a cold war that could veer into conflict.

Read more expert-driven national security insights, perspective and analysis in The Cipher Brief

The post How to Avoid Cold War with China appeared first on The Cipher Brief.

find more fun & mates at SoShow now !

As infections are rising again, scientists all around the world are rushing to fight the danger, offering a choice of new treatments and unusual variants of vaccines.

Levels of contagion are setting new records, hospitals are overwhelmed, governments are starting to introduce lockdowns, and not only for unvaccinated people ​​– the picture of the fight against Covid-19 looks quite disappointing. However, there’s still a place for good news: Research teams report positive results while trialling new medicines and vaccine types.

Nasal vaccines 

Vaccination will remain one of the most effective tools against Covid-19. As Professor David Dockrell, from the Center for Inflammation Research of the University of Edinburgh, told RT, “vaccines will continue to be a central part of how we control the virus.”

“If we can dampen down the number of infections, and the severity of infections, and also the extent to which the virus can replicate in people when they become infected, then we are slowing down the ability of the virus to change and to mutate,” he explains. 

So I think the vaccines still will be a very important part of the preventive strategy. It’s vital that they are available to all the world’s population, irrespective of where people live, and the wealth of the country in which they live. 

However, vaccination doesn’t always mean you have to get an injection. For instance, several intranasal Covid-19 vaccines are currently being developed. As the virus gets into the body through the nose, a nasal spray or drops are aimed to produce mucosal immune response and prevent it from getting into the lungs.

In India, a vaccine of this type is already completing Phase 2 of clinical trials. In Russia, a nasal vaccine is undergoing a clinical trial on volunteers. In Thailand, a home-developed product is expected to be trialed on humans next spring. In the US, Universities of Houston and Stanford recently reported good results of their experiments carried out on mice.

Read more

A security guard checks vaccination certificates outside a business in Athens, Greece, November 6, 2021.
Another EU state to ban unvaccinated from indoor spaces

Intranasal vaccines can have several potential benefits compared to inoculation. 

“They would be easier to use, because they can be self-administered. They wouldn’t need a nurse or clinical settings,” Swedish professor emeritus of epidemiology Marcello Ferrada de Noli explained to RT. As a result, he says, there’s hope that fewer people will be reluctant to be immunized. Not so many of us find it pleasant to get a jab ​​– and after all, there are those who are just afraid of needles. Also, it would be much easier to vaccinate children with nasal substances. 

However, what concerns Prof. de Noli the most is the duration of the effect of a vaccine of this type. Still, scientists can’t say for sure whether a nasal substance may completely replace a shot. According to Alexander Gintsburg, the head of Moscow’s Gamaleya Center biomedical research institute, which created the Sputnik V vaccine, the nasal version they are working on would serve for an additional protection against the virus, but would not replace the injections.

Chew the virus away? 

A nasal vaccine is not the only one being developed. In summer, it was revealed that Russian Defense Ministry scientists were creating a ‘chewing gum’ vaccine, also targeting the mucosal immune response. Meanwhile, a UK firm announced this month that it would conduct a human trial of a skin patch that uses T-cells to confront the virus. Developers hope it would offer longer-lasting immunity than the existing vaccines. Work on a similar project is being done in the University of Queensland, Australia.

While it all looks so promising, Prof. de Noli warns that it would still take a lot of time until these products become available to the public. “I think that discoveries in this field are a very good thing. But if we say ‘We discovered a new type of vaccine’, people will say ‘Aha, so I’m going to wait’. But we need to vaccinate people now,” he points out.

Improving Covid treatment

Vaccines are not a silver bullet, unfortunately, given the not-so-high level of global immunization and the constantly emerging new strains of the virus. “People might get infected despite having had a vaccine, but I still think the vaccine strategy is going to be central to how we manage this kind of virus going forward,” Prof. Dockrell says. “But we will have other strategies that will be very important. We will have other elements. When we put them all together, it gives us the best opportunity that people can live with coronaviruses, and hopefully, the mortality can be limited to much lower extense than what we’ve sadly seen in the last eighteen months.”

Read more

© Don Emmert/AFP
Pfizer widens access to its anti-Covid pill

Monoclonal antibodies will be central to the ongoing vaccine strategy, Prof. Dockrell explains. These are the antibodies similar to those the body uses to fight the virus. They are produced in labs and given via infusion or injection to boost the patient’s response against certain diseases. Monoclonal antibody treatment is used for people under a high risk of developing severe infection (including older patients 65+ years old or those with chronic medical conditions). It’s already being used in the US, following last year’s FDA approval. Earlier in November, the European Medicines agency recommended authorizing two monoclonal antibody medicines.

In October, UK’s AstraZeneca reported positive results of a Phase 3 study of its antibody combination, which, according to developers, is highly effective in both prevention and treatment of coronavirus.

Researchers are also working on a possibility to save Covid-infected patients from the so-called ‘cytokine storm’ – a situation when the immune system reacts so intensely that kills not only the virus, but the whole organism itself. A drug to ‘calm the storm’ was registered in Russia this year, and it’s already being used on patients.

Another way to fight Covid-19 is to use antiviral drugs. When the pandemic started, medics had to use something already existing (like anti-influenza Favipiravir) or something being authorized for emergency use (like remdesivir). Now, more than a year on, the work to create a special drug to specifically cure Covid-19 is giving its results. This month, Russia registered its first injectable anti-Covid medicine. A bit earlier, the UK became the first country to approve an antiviral pill produced by the US-based companies Merck and Ridgeback Biotherapeutics. Another American firm, Pfizer, got positive results from trials of its drug of the same kind. Both firms hope that with a drug in the form of a pill it would be easier to treat people at home.

Appreciating all the efforts on the field of developing anti-Covid treatment, Prof. de Noli points out that still, the key issue now is to reduce the spreading of the virus. “The new medicines are developed for people who already got the disease,” he says.

But we need to prevent people from getting the infection, not let them get infected because we have some new medicine that can cure them.

The same idea is echoed by scientists all over the world quoted in plenty of articles dedicated to the medical gains: it’s great to have the treatment, but none of the drugs may substitute vaccination, as first and foremost, humanity has to adopt preventive measures and stop the pandemic.

If you like this story, share it with a friend!

find more fun & mates at SoShow now !